Volume | 78,196 |
|
|||||
News | - | ||||||
Day High | 16.225 | Low High |
|||||
Day Low | 14.69 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Avalo Therapeutics Inc | AVTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
15.00 | 14.69 | 16.225 | 15.94 | 14.98 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,005 | 78,196 | $ 15.36 | $ 1,201,314 | - | 3.9501 - 1,130.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:46:33 | 60 | $ 15.52 | USD |
Avalo Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.35M | 801.61k | - | 1.92M | -31.54M | -39.35 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Avalo Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AVTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.68 | 16.32 | 11.46 | 13.47 | 84,127 | 4.26 | 36.47% |
1 Month | 19.00 | 22.47 | 11.10 | 16.10 | 304,404 | -3.06 | -16.11% |
3 Months | 4.61 | 34.46 | 4.0101 | 19.35 | 716,683 | 11.33 | 245.77% |
6 Months | 25.92 | 34.46 | 3.9501 | 18.03 | 11,223,074 | -9.98 | -38.50% |
1 Year | 712.80 | 1,130.40 | 3.9501 | 33.37 | 23,586,247 | -696.86 | -97.76% |
3 Years | 688.80 | 1,711.20 | 3.9501 | 39.32 | 8,976,055 | -672.86 | -97.69% |
5 Years | 688.80 | 1,711.20 | 3.9501 | 39.32 | 8,976,055 | -672.86 | -97.69% |
Avalo Therapeutics Description
Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006. |